In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Julia L. Hurwitz, PhD
Member, St. Jude Faculty
Departments
Infectious Diseases
Contact Information
Julia Hurwitz, PhD
Infectious Diseases
MS 320, Room E-8052
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: julia.hurwitz@stjude.org
Phone: (901) 595-2464
FAX: (901) 595-3099
Education
PhD - Johns Hopkins University, Baltimore, Maryland (1981)
Research Interests
- T-cell development/activation/immunotherapy
- T-cell receptor gene rearrangement
- HIV vaccine development
- Respiratory virus vaccine development
- EBV vaccine development
Selected Publications
Hurwitz JL, Shenep JL, Russell CJ, Portner A. Development of Sendai virus-based vaccines to prevent pediatric respiratory virus infections. Procedia in Vaccinology 2009 (in press).
Sealy R, Zhan X, Lockey TD, Martin L, Blanchard J, Traina-Dorge V, Hurwitz JL. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: A gold-standard for HIV-1 vaccine development? Current HIV Research 2009 (in press).
Surman SL, Sealy R, Jones BG, Hurwitz JL. HIV-1 vaccine design: Harnessing diverse lymphocytes to conquer a diverse pathogen (NIHMS #89672). Human Vaccines 2009 (in press).
Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL. Human PIV-2 recombinant Sendai Virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3 and RSV. Vaccine 27: 1848-1857, 2009.
Sealy R, Slobod K, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL. Pre-clinical and clinical development of a multi-envelope DNA-Virus-Protein (D-V-P) HIV-1 vaccine (PMCID# PMC2649747). International Reviews Immunol 28: 49-68, 2009.
Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza virus and respiratory syncytial virus infections. Pediatr Inf Dis J 27: S126-128, 2008.
Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, Surman S, Russell CJ, Portner A, Hurwitz JL. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 26: 3480-3488, 2008.
Lockey TD, Zhan X, Sample CE, Hurwitz JL. Developing an Epstein-Barr virus vaccine: Eliciting responses toward lytic and latent proteins with a cocktail vaccine approach. Front Bioscience 13: 5916-5927, 2008.
Sealy R, Chaka WS, Surman S, Brown S, Cresswell P, Hurwitz JL.Target peptide sequence within infectious HIV-1 does not ensure envelope-specific T-helper cell re-activation: influences of cysteine protease and gamma-interferon induced thiol reductase activities. Clin Vaccine Immunol 15: 713-719, 2008.
Hurwitz JL, Lockey T, Jones B, Freiden P, Sealy R, Coleman J, Howlett N, Branum K, Slobod KS. First Phase I clinical safety trial of an HIV-1 subtype D gp140 envelope protein vaccine: Immunogenicity induced among all study participants. AIDS 22: 149-158, 2008.
Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS. HIV-1 vaccine development: Tackling virus diversity with a multi-envelope cocktail. Front Bioscience 13: 609-620, 2008.
Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, Surman S, Portner A, Slobod KS. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell immune responses and confers complete protection against RSV A and B isolates. Vaccine 25: 8782-8793, 2007.
Brown SA, Hurwitz JL, Zirkel A, Surman S, Takimoto T, Alymova I, Coleclough C, Portner A, Doherty PC, Slobod S. A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted HIV envelope glycoprotein. J Virol 81: 12535-12542, 2007.
Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Jones B, Surman S, Sealy R, Freiden P, Branum K, Slobod KS. Keynote Lecture: A multi-vector, multi-envelope HIV-1 vaccine. J Pediatr Pharm Ther 12: 68-76, 2007.
Bonsignori M, D'Costa S, Surman S, Hurwitz JL. A combination of 5-fluorouracil and membrane-bound antibody inhibits B-cell lymphoma growth in a mouse model system. Leuk Lymphoma 48: 406-409, 2007.
Zhan X, Hurwitz JL, Brown SA, Slobod KS. HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulations. AIDS Res Hum Retroviruses 23: 471-476, 2007.
Brown SA, Slobod KS, Surman S, Zirkel A, Zhan X, Hurwitz JL. Individual HIV-1 envelope-specific T-cell responses and epitopes do not segregate by virus subtype. AIDS Res Hum Retroviruses 22: 188-194, 2006.
Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, Stambas J, Bonsignori M, Sealy RE, Blanchard JL, Hurwitz JL. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23: 5306-5320, 2005.
Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd K, Scroggs RA, Portner A, Slobod KS. Recombinant Sendai virus as a novel vaccine candidate for Respiratory Syncytial Virus. Viral Immunology 18: 255-265, 2005.
Slobod KS, Bonsignori M, Brown SA, Zhan X, Stambas J, Hurwitz JL. HIV vaccines: Brief review and discussion of future directions. Expert Rev Vaccines 4:305-313, 2005.
Madzikanga M, Kangwende A, Pfumojena J, Slobod KS, Hurwitz JL. The HIV pandemic: A forgotten crisis? Current Drug Targets-Infectious Disorders 5:85, 2005.
Hurwitz JL. Preface: HIV vaccine discovery and development. Current Drug Targets-Infectious Disorders 5: 81-83, 2005.
Brown SA, Hurwitz JL, Zhan X, Doherty PC, Slobod KS. CD8+ T-cells: Are they sufficient to prevent, contain or eradicate HIV-1 Infection? Current Drug Targets-Infectious Disorders 5: 113-119, 2005.
Hurwitz JL, Slobod K, Lockey T, Wang S, Chou T-HW, Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Current Drug Targets-Infectious Disorders 5: 143-156, 2005.
Coleclough C, Sealy R, Surman S, Marshall DR, Hurwitz JL. Respiratory vaccination of mice against influenza virus: Dissection of T and B cell priming functions. Scand J Immunology 62 (suppl 1): 73-83, 2005.
Slobod KS, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, Zirkel A, Jones B, Sealy B, Stambas J, Brown B, Lockey TD, Freiden P, Doherty PC, Martin L, Hurwitz JL. HIV Vaccine Rationale, Design and Testing. Curr HIV Research 3: 107-112, 2005.
Slobod KS, Coleclough C, Brown SA, Stambas J, Zhan X, Surman S, Jones BG, Zirkel A, Freiden PJ, Brown B, Sealy R, Bonsignori M, Hurwitz JL. Clade, country and region-specific HIV-1 vaccines: Are they necessary? AIDS Research and Therapy 2:3, April 2005.
Stambas J, Brown SA, Gutierrez A, Sealy B, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 23: 2454-2464, 2005.
Brown SA, Lockey TD, Slaughter C, Slobod KS, Surman S, Zirkel A, Mishra A, Pagala VR, Coleclough C, Doherty PC, Hurwitz JL. T-cell epitope “hotspots” on the HIV-1 envelope protein overlap with tryptic fragments displayed by mass spectrometry. AIDS Res Hum Retroviruses 21:165-170, 2005.
Slobod KS, Brown SA, Surman S, Zirkel A, Jones B, Zhan X, Sealy B, Stambas J, Brown B, Bonsignori M, Lockey TD, Freiden P, Hurwitz JL, Doherty PC, Coleclough C. Overcoming diversity with a multi-envelope vaccine. Curr Topics Virol 4:159-168, 2004.
Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits protection against RSV. J Virol 78:6043-6047, 2004.
Slobod KS, Shenep JL, Lujan-Zilberman J, Portner A, Coleclough C, Hurwitz JL. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy adults. Vaccine 22: 3182-3186, 2004.
Zhan X, Slobod KS, Surman S, Brown SA, Coleclough C, Hurwitz J. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine 22:1206-1213, 2004.
Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ, Doherty PC, Hurwitz JL. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Micro Inf Dis 23: 106-110, 2004.
D’Costa S, Hurwitz JL. Phytohemagglutinin inhibits lymphoid tumor growth in vitro and in vivo. Leuk Lymph 44: 1785-1791, 2003.
D’Costa S, Hurwitz JL. Customized mitogen or antibody treatments enhance the sensitivity of lymphoid tumors to 5-fluorouracil in vitro and in vivo. Leuk Lymph 44:841-847, 2003.
Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, Zirkel A, Surman S, White SW, Doherty PC, Hurwitz JL. Clustering of T helper cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J Immunol 171: 4140-4148, 2003.
Zhan X, Brown B, Slobod KS, Hurwitz JL. Inhibition of Ex Vivo-Expanded Cytotoxic T-Lymphocyte Function by High-Dose Cyclosporin A. Transplantation 76: 739-741, 2003.
Sealy R, Surman S, Hurwitz JL, Coleclough C. Antibody response to influenza infection of mice: Different patterns for glycoprotein and nucleocapsid antigens. Immunology 108:431-439, 2003.
Zhan X, Slobod KS, Surman S, Brown SA, Lockey TD, Coleclough C, Doherty PC, Hurwitz JL. Limited Breadth of a T-helper cell response to an HIV envelope Protein. J Virol 77: 4231-4236, 2003
D’Costa S, Slobod KS, Hurwitz JL. Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth? Leuk Lymph 44:139-142, 2003.
Last update: May 2009
